- Ipidacrine
-
- $29.00
-
2026-05-11
- CAS:62732-44-9
- Purity: 99.99%
- Supply Ability: 10g
|
| | 2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA[B]QUINOLIN-9-YLAMINE Basic information |
| Product Name: | 2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA[B]QUINOLIN-9-YLAMINE | | Synonyms: | 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrochloride;MFCD11052605;1H,2H,3H,5H,6H,7H,8H-Cyclopenta[b]quinolin-9-amine;CBI-BB ZERO/005050;AURORA KA-7699;2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA[B]QUINOLIN-9-YLAMINE;9-AMINO-2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA[B]QUINOLINE;AKOS MSC-0106 | | CAS: | 62732-44-9 | | MF: | C12H16N2 | | MW: | 188.27 | | EINECS: | 676-166-9 | | Product Categories: | | | Mol File: | 62732-44-9.mol | ![2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA[B]QUINOLIN-9-YLAMINE Structure](CAS/GIF/62732-44-9.gif) |
| | 2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA[B]QUINOLIN-9-YLAMINE Chemical Properties |
| Melting point | 202-203 °C(Solv: methanol (67-56-1); water (7732-18-5)) | | Boiling point | 368.0±42.0 °C(Predicted) | | density | 1.170±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMF: 25 mg/ml,DMSO: 25 mg/ml,DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml | | form | A solid | | pka | 10.88±0.20(Predicted) | | color | White to off-white |
| Hazard Codes | Xi | | Hazard Note | Irritant |
| | 2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA[B]QUINOLIN-9-YLAMINE Usage And Synthesis |
| Uses | Ipidacrine is used in biological studies as a possible treatment of toxic cognitive disorders. | | Definition | ChEBI: 2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-9-amine is an aminoquinoline. | | in vivo | Ipidacrine (1 mg/kg, p.o., repeated and a single dose for 5 days) by repeated administration has more potent antiamnesic effects than by single administration in induced by nucleus basalis of meynert (NBM) induced rats[1].
Ipidacrine (10 mg/kg p.o., a single dose) significantly decreases spontaneous movements, which is more selective as an antiamnesic than either Tacrine (HY-111338) and E-2020 (HY-B0034) in rats[1].
Ipidacrine (6.7 mg/kg, intragastrically, daily for 14 days) leads to statistically more efficient evolving of intracavernous pressure (ICPmax)/maxipressure (MAP) compared with control group in Streptozotocin (STZ) (HY-13753)-induced diabetic rats[3].
| Animal Model: | Rats[1] | | Dosage: | 1 mg/kg | | Administration: | p.o., repeated and a single dose for 5 days | | Result: | The repeated administration of ipidacrine improved amnesia induced by nucleus basalis of meynert (NBM) lesions in the passive avoidance task in rats. |
| Animal Model: | Rats[1] | | Dosage: | 3, 10, 30 mg/kg | | Administration: | p.o., a single dose | | Result: | Decreased pupil size and increased salivation at 3 mg/kg, decreased spontaneous movements at 10 mg/kg and decreased body temperature and induced tremor at 30 mg/kg in rats. |
| Animal Model: | Rats with streptozotocin (STZ) (HY-13753) induced diabetes mellitus-induced erectile dysfunction (DMED)[1] | | Dosage: | 6.7 mg/kg | | Administration: | crushed, suspended in 1% starch solution and administered intragastrically daily for 14 days | | Result: | Ipidacrine was as effective as sildenafil and could significantly improve DMED symptoms. |
|
| | 2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA[B]QUINOLIN-9-YLAMINE Preparation Products And Raw materials |
|